Cardiotoxic effects of the novel approved anti-ErbB2 agents and reverse cardioprotective effects of ranolazine

PURPOSE: Pertuzumab, a novel anti-epidermal growth factor receptor 2 humanized monoclonal antibody, and trastuzumab-emtansine (TDM1), a novel antibody–drug conjugate made up of trastuzumab covalently linked to the highly potent microtubule inhibitory agent DM1, have been recently approved by the US...

Descripción completa

Detalles Bibliográficos
Autores principales: De Lorenzo, Claudia, Paciello, Rolando, Riccio, Gennaro, Rea, Domenica, Barbieri, Antonio, Coppola, Carmela, Maurea, Nicola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5914739/
https://www.ncbi.nlm.nih.gov/pubmed/29719406
http://dx.doi.org/10.2147/OTT.S157294

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5914739/
https://www.ncbi.nlm.nih.gov/pubmed/29719406
http://dx.doi.org/10.2147/OTT.S157294

Ejemplares similares